Weisenberger H - Search Results

1

PK/PD simulations as a tool for rational design of clinical dosage regimens: an example with Fradafiban.

Brickl R, Heinzel G, Weisenberger H, Schubert H, Rutsch W, Roth W. Brickl R, et al. Among authors: weisenberger h. Int J Clin Pharmacol Ther. 1997 Oct;35(10):475-80. Int J Clin Pharmacol Ther. 1997. PMID: 9352399 Clinical Trial.

2

Pharmacokinetic-pharmacodynamic and metabolite modeling with TopFit.

Tanswell P, Heinzel G, Weisenberger H, Roth W. Tanswell P, et al. Among authors: weisenberger h. Int J Clin Pharmacol Ther. 1995 Oct;33(10):550-4. Int J Clin Pharmacol Ther. 1995. PMID: 8574505

3

Dipyridamole alone or combined with low-dose acetylsalicylic acid inhibits platelet aggregation in human whole blood ex vivo.

Müller TH, Su CA, Weisenberger H, Brickl R, Nehmiz G, Eisert WG. Müller TH, et al. Among authors: weisenberger h. Br J Clin Pharmacol. 1990 Aug;30(2):179-86. doi: 10.1111/j.1365-2125.1990.tb03763.x. Br J Clin Pharmacol. 1990. PMID: 2206782 Free PMC article. Clinical Trial.

4

Inhibition of platelet aggregation as a surrogate marker.

Narjes H, Müller TH, Weisenberger H, Guth B, Brickl R. Narjes H, et al. Among authors: weisenberger h. J Clin Pharmacol. 1997 Jan;37(S1):59S-64S. doi: 10.1177/009127009703700123. J Clin Pharmacol. 1997. PMID: 9048286 Review.

5

Profound and sustained inhibition of platelet aggregation by Fradafiban, a nonpeptide platelet glycoprotein IIb/IIIa antagonist, and its orally active prodrug, Lefradafiban, in men.

Müller TH, Weisenberger H, Brickl R, Narjes H, Himmelsbach F, Krause J. Müller TH, et al. Among authors: weisenberger h. Circulation. 1997 Aug 19;96(4):1130-8. doi: 10.1161/01.cir.96.4.1130. Circulation. 1997. PMID: 9286940 Clinical Trial.

6

Antagonism of the GPIIb/IIIa receptor with the nonpeptidic molecule BIBU52: inhibition of platelet aggregation in vitro and antithrombotic efficacy in vivo.

Guth BD, Seewaldt-Becker E, Himmelsbach F, Weisenberger H, Müller TH. Guth BD, et al. Among authors: weisenberger h. J Cardiovasc Pharmacol. 1997 Aug;30(2):261-72. doi: 10.1097/00005344-199708000-00017. J Cardiovasc Pharmacol. 1997. PMID: 9269956

7

Pharmacokinetics of oral dipyridamole (Persantine) and its effect on platelet adenosine uptake in man.

Dresse A, Chevolet C, Delapierre D, Masset H, Weisenberger H, Bozler G, Heinzel G. Dresse A, et al. Among authors: weisenberger h. Eur J Clin Pharmacol. 1982;23(3):229-34. doi: 10.1007/BF00547559. Eur J Clin Pharmacol. 1982. PMID: 6756935 Clinical Trial.

8

Guanidine derivatives as combined thromboxane A2 receptor antagonists and synthase inhibitors.

Soyka R, Guth BD, Weisenberger HM, Luger P, Müller TH. Soyka R, et al. Among authors: weisenberger hm. J Med Chem. 1999 Apr 8;42(7):1235-49. doi: 10.1021/jm9707941. J Med Chem. 1999. PMID: 10197967

9

6,6-Disubstituted Hex-5-enoic acid derivatives as combined thromboxane A2 receptor antagonists and synthetase inhibitors.

Soyka R, Heckel A, Nickl J, Eisert W, Müller TH, Weisenberger H. Soyka R, et al. Among authors: weisenberger h. J Med Chem. 1994 Jan 7;37(1):26-39. doi: 10.1021/jm00027a004. J Med Chem. 1994. PMID: 8289199

10

Bioequivalence of two dipyridamole preparations and inhibitory effect on the platelet adenosine uptake in man.

Chevolet C, Van de Velde V, Weisenberger H, Herman A, Dresse A. Chevolet C, et al. Among authors: weisenberger h. Arch Int Pharmacodyn Ther. 1981 Oct;253(2):321-2. Arch Int Pharmacodyn Ther. 1981. PMID: 7325769 No abstract available.

Save citations to file

Email citations

Send citations to clipboard

Add to Collections

Add to My Bibliography

Create a file for external citation management software

Your saved search

Your RSS Feed

My Custom Filters

Publication date

Text availability

Article attribute

Article type

Article Language

Species

Sex

Age

Other

24 results

Search Page

Filters